Modern Mobility Aids, Inc. (MDRM) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerModern Mobility Aids, Inc. (MDRM) trades at $0.005. Modern Mobility Aids Inc. is innovating telehealth by replicating in-person consultations through advanced technology. Their platform connects patients and doctors remotely, facilitating thorough examinations via software, medical devices, and AI. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for MDRM: MDRM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Modern Mobility Aids, Inc. (MDRM) Healthcare & Pipeline Overview
Modern Mobility Aids Inc. is pioneering a telehealth platform that emulates traditional in-person consultations using software, medical devices, and AI. This innovative approach aims to enhance remote patient care and physician capabilities, distinguishing it within the evolving healthcare information services sector.
What Is the Investment Thesis for MDRM?
Modern Mobility Aids Inc. presents a notable research candidate within the rapidly growing telehealth market. The company's innovative platform, which replicates in-person consultations using advanced technology, addresses a critical need for accessible and high-quality remote healthcare. Key value drivers include the increasing adoption of telehealth services, the potential for cost savings in healthcare delivery, and the company's ability to expand its platform to new therapeutic areas and geographic markets. However, investors may want to evaluate the risks associated with operating in the OTC market, including limited liquidity and regulatory uncertainties. As of 2026-03-16, the company's P/E ratio is -1.49, reflecting its current earnings status.
Based on FMP financials and quantitative analysis
MDRM Key Highlights
Innovative telehealth platform replicating in-person consultations using software, medical devices, and AI.
- Focus on improving patient outcomes and reducing healthcare costs through remote medical care.
- Expansion opportunities into new therapeutic areas and geographic markets.
- Trades on the OTC market, offering potential for high growth but also higher risk.
- P/E ratio of -1.49, indicating the company is not currently profitable but has growth potential.
Who Are MDRM's Competitors?
MDRM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.52 | -4.35% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.48 | -0.24% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.45 | -0.58% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.83 | +3.52% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $5.87 | -6.97% | $25.5M | — |
| YI 111, Inc. | $3.25 | +0.78% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.34 | -1.58% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDRM's Key Strengths?
Innovative telehealth platform replicating in-person consultations.
- Strong focus on improving patient outcomes and reducing healthcare costs.
- Potential for expansion into new therapeutic areas and geographic markets.
- Use of AI to enhance diagnostic capabilities.
What Are MDRM's Weaknesses?
Limited operating history and brand recognition.
- Reliance on technology and potential for technical issues.
- Dependence on regulatory approvals and reimbursement policies.
- Trades on the OTC market, which carries additional risks.
What Are the Key Risks for MDRM?
Financial-distress signal — its Altman Z-Score of -39.39 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established telehealth providers with greater resources and market share.
- Changes in regulatory policies and reimbursement rates for telehealth services.
- Dependence on technology and potential for technical issues or cybersecurity threats.
- Limited liquidity and price volatility due to trading on the OTC market.
- Uncertainty regarding the company's financial performance and ability to achieve profitability.
What Threats Does MDRM Face?
- Competition from established telehealth providers.
- Rapid technological advancements and potential for obsolescence.
- Changes in regulatory policies and reimbursement rates.
- Economic downturn and reduced healthcare spending.
What Are MDRM's Competitive Advantages?
- Proprietary telehealth platform with advanced features and capabilities.
- Strong focus on replicating the in-person consultation experience.
- Potential for network effects as more healthcare providers and patients join the platform.
What Does MDRM Do?
Modern Mobility Aids Inc., based in Brampton, Canada, is focused on transforming the healthcare experience by developing a telehealth platform that mirrors the interactions of a traditional in-person clinic. The company's solution leverages advanced software, medical devices, and artificial intelligence to enable real-time, comprehensive remote consultations between patients and physicians. This technology allows doctors to conduct thorough examinations as if the patient were physically present, enhancing the quality and accessibility of healthcare services. The company's core offering is a telehealth platform designed to replicate the face-to-face experience of a doctor's visit. This includes the use of specialized medical devices that transmit real-time data to the physician, allowing for accurate diagnoses and treatment plans. By combining these technologies, Modern Mobility Aids aims to improve patient outcomes, reduce healthcare costs, and expand access to medical care, particularly in underserved areas. Modern Mobility Aids Inc. is committed to making a significant social impact by improving people's health through innovative telehealth solutions.
What Products and Services Does MDRM Offer?
- Develop a telehealth platform that replicates in-person consultations.
- Utilize software, medical devices, and AI to facilitate remote examinations.
- Connect patients and doctors in real-time for comprehensive healthcare.
- Enable physicians to conduct thorough examinations remotely.
- Improve patient outcomes through accessible telehealth solutions.
- Reduce healthcare costs by providing remote medical care.
- Expand access to medical care, particularly in underserved areas.
How Does MDRM Make Money?
- Subscription fees from healthcare providers for access to the telehealth platform.
- Revenue from the sale of medical devices used in remote consultations.
- Potential for partnerships with insurance providers for reimbursement of telehealth services.
What Industry Does MDRM Operate In?
Modern Mobility Aids Inc. operates within the healthcare information services industry, a sector experiencing rapid growth due to the increasing adoption of telehealth and remote patient monitoring. The market is driven by factors such as the aging population, rising healthcare costs, and advancements in technology. The competitive landscape includes established telehealth providers and emerging technology companies. Modern Mobility Aids differentiates itself through its focus on replicating the in-person consultation experience, offering a more comprehensive and personalized approach to remote healthcare. This positions the company to capitalize on the growing demand for accessible and high-quality telehealth services.
Who Are MDRM's Key Customers?
- Healthcare providers, including doctors, clinics, and hospitals.
- Patients seeking convenient and accessible healthcare services.
- Insurance companies looking to reduce healthcare costs and improve patient outcomes.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an unknown, not an operating company
Company Profile
Modern Mobility Aids, Inc. operates in the Healthcare sector. It is headquartered in Brampton, CA. The company is led by CEO Tito Di Marco. MDRM has traded publicly since 2014.
Key Financial Metrics
Return on equity for Modern Mobility Aids, Inc. stands at 2.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.20 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -1.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Modern Mobility Aids, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.39 places it in the distress zone, a signal of elevated financial risk.
MDRM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative telehealth platform replicating in-person consultations.
- Strong focus on improving patient outcomes and reducing healthcare costs.
- Potential for expansion into new therapeutic areas and geographic markets.
- Use of AI to enhance diagnostic capabilities.
Bear Case
- Limited operating history and brand recognition.
- Reliance on technology and potential for technical issues.
- Dependence on regulatory approvals and reimbursement policies.
- Trades on the OTC market, which carries additional risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MDRM Latest News
No recent news available for MDRM.
MDRM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MDRM.
Price Targets
Wall Street price target analysis for MDRM.
MDRM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MDRM; grades run from A+ (80-100) to F (below 30).
Leadership: Tito DiMarco
CEO
Tito DiMarco is the Chief Executive Officer of Modern Mobility Aids Inc. His background includes experience in healthcare technology and business development. He has a track record of leading innovative projects and driving growth in the healthcare sector. DiMarco's expertise lies in identifying market opportunities and developing strategies to capitalize on them, with a focus on improving patient outcomes and reducing healthcare costs. His leadership is focused on expanding the reach of Modern Mobility Aids' telehealth platform.
Track Record: Under Tito DiMarco's leadership, Modern Mobility Aids Inc. has focused on developing and launching its telehealth platform. Key milestones include securing partnerships with healthcare providers and expanding the platform's capabilities to include remote monitoring and AI-powered diagnostics. DiMarco has also overseen the company's efforts to navigate the regulatory landscape and secure reimbursement for its telehealth services. His strategic decisions have positioned the company for growth in the rapidly evolving telehealth market.
MDRM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Modern Mobility Aids Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase the risk of investing in these securities. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited liquidity and potential for price volatility.
- Lack of regulatory oversight and financial reporting requirements.
- Higher risk of fraud or manipulation compared to listed stocks.
- Potential for delisting or suspension of trading.
- Limited access to capital and financing opportunities.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company website with detailed information about its business and products.
- Presence of a management team with relevant experience.
- Positive media coverage or industry recognition.
- Partnerships with reputable healthcare providers or organizations.
Common Questions About MDRM (Healthcare)
What do analysts say about MDRM stock?
As of 2026-03-16, there is no readily available analyst consensus on Modern Mobility Aids Inc. due to its OTC market listing and limited coverage. Key valuation metrics, such as revenue growth and profitability, are still developing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market investments carry higher risk than exchange-listed stocks.